Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

NCT04869228 is registered in ClinicalTrials.gov with Suzhou Kintor Pharmaceutical Inc, as lead sponsor.

NCT NCT04869228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04869228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Phase
Phase 3
Overall status
Terminated
Start date
August 4, 2021
Completion date
August 2, 2023
Enrollment
380 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19